Clinical Trials

Multiple clinical trials are currently evaluating interventions for constipation management, encompassing chronic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation. Ranging from completed to not yet recruiting, these studies include Phase 4 and non-applicable phase protocols evaluating laxative efficacy and colonic motor function. The trial landscape involves major academic institutions—including Nanyang Technological University, National University of Singapore, and KU Leuven—alongside industry sponsors such as Shire and Takeda.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06219707 Not yet recruiting
Irritable Bowel Syndrome With Constipation
Nanyang Technological University|National University of Singapore
 2024-03-01 Not Applicable
NCT05770960 Completed
Opioid-Induced Constipation
Universitaire Ziekenhuizen KU Leuven
 2018-06-27 Phase 4
NCT03279341 Completed
Chronic Constipation
University Hospital Gasthuisberg
 2012-12-03 Phase 4
NCT01424228 Completed
Constipation
Shire|Takeda
 2011-04-06 Phase 4

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Bisacodyl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Bisacodyl functions as a prodrug that undergoes enzymatic cleavage in the lower gastrointestinal tract to produce its active metabolite, which directly stimulates enteric plexus nerves and mucosal cells in the colon. This neuro-epithelial activation enhances electrolyte secretion and triggers localized propulsive peristalsis, thereby accelerating intestinal transit to relieve symptoms in clinical conditions such as chronic constipation, constipation, and opioid-induced constipation.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.